Veit J. Erpenbeck
- Safety, tolerability and pharmacokinetics of an oral competitive reversible CRTh2 antagonist, QAW039, in healthy subjectsBy Veit J. Erpenbeck, Eva Vets, Lien Gheyle, Wande Osuntokun, Michael Larbig, Srikanth Neelakantham, Gerald Dubois and Sheryl PerryVeit J. Erpenbeck1Primary Care, Novartis Pharma AG, Basel, SwitzerlandEva Vets2Life Sciences, SGS-Life Sciences, Antwerp, BelgiumLien Gheyle2Life Sciences, SGS-Life Sciences, Antwerp, BelgiumWande Osuntokun4Primary Care, Novartis Pharmaceuticals UK Limited, Horsham, United KingdomMichael Larbig1Primary Care, Novartis Pharma AG, Basel, SwitzerlandSrikanth Neelakantham3Integrated Information Sciences, Novartis Healthcare Pvt. Ltd., Hyderabad, IndiaGerald Dubois4Primary Care, Novartis Pharmaceuticals UK Limited, Horsham, United KingdomSheryl Perry4Primary Care, Novartis Pharmaceuticals UK Limited, Horsham, United Kingdom
- Safety, tolerability and pharmacokinetics of QAV680, an oral CRTh2 antagonist, in healthy subjectsBy Veit J. Erpenbeck, Rainard Fuhr, Gerald Dubois and Sheryl PerryVeit J. Erpenbeck1Primary Care, Novartis Pharma AG, Basel, SwitzerlandRainard Fuhr2Early Phase Clinical Unit, PAREXEL International GmbH, Berlin, GermanyGerald Dubois3Primary Care, Novartis Pharmaceuticals UK Limited, Horsham, West Sussex, United KingdomSheryl Perry3Primary Care, Novartis Pharmaceuticals UK Limited, Horsham, West Sussex, United Kingdom
- Efficacy and safety of 10 day treatment with the CRTh2 antagonist QAV680 evaluated in patients with allergic rhinitis in an environmental exposure chamberBy Veit J. Erpenbeck, Ann Marie Salapatek, Piyush Patel, Johanne Sanni, Gerald Dubois, Ping Zhou, Sheryl Perry and Michael LarbigVeit J. Erpenbeck1Primary Care, Novartis Pharma AG, Basel, SwitzerlandAnn Marie Salapatek2Clinical Research, Inflamax Research Inc., Toronto, ON, CanadaPiyush Patel2Clinical Research, Inflamax Research Inc., Toronto, ON, CanadaJohanne Sanni3Primary Care, Novartis Pharmaceuticals UK Limited, Horsham, West Sussex, United KingdomGerald Dubois3Primary Care, Novartis Pharmaceuticals UK Limited, Horsham, West Sussex, United KingdomPing Zhou3Primary Care, Novartis Pharmaceuticals UK Limited, Horsham, West Sussex, United KingdomSheryl Perry3Primary Care, Novartis Pharmaceuticals UK Limited, Horsham, West Sussex, United KingdomMichael Larbig1Primary Care, Novartis Pharma AG, Basel, Switzerland
- QAV680, cetirizine and their combination reduce nasal symptoms in patients with intermittent allergic rhinitis in an environmental exposure chamberBy Veit J. Erpenbeck, Anne Marie Salapatek, Piyush Patel, Deanne Carew, Gerald Dubois, Sheryl Perry and Michael LarbigVeit J. Erpenbeck1Primary Care, Novartis Pharma AG, Basel, SwitzerlandAnne Marie Salapatek2Clinical Research, Inflamax Research Inc, Toronto, ON, CanadaPiyush Patel2Clinical Research, Inflamax Research Inc, Toronto, ON, CanadaDeanne Carew3Primary Care, Novartis Pharmaceuticals UK Limited, Horsham, West Sussex, United KingdomGerald Dubois3Primary Care, Novartis Pharmaceuticals UK Limited, Horsham, West Sussex, United KingdomSheryl Perry3Primary Care, Novartis Pharmaceuticals UK Limited, Horsham, West Sussex, United KingdomMichael Larbig1Primary Care, Novartis Pharma AG, Basel, Switzerland
- Clinical and inflammatory characteristics of the European U-BIOPRED adult severe asthma cohortBy Dominick E. Shaw, Ana R. Sousa, Stephen J. Fowler, Louise J. Fleming, Graham Roberts, Julie Corfield, Ioannis Pandis, Aruna T. Bansal, Elisabeth H. Bel, Charles Auffray, Chris H. Compton, Hans Bisgaard, Enrica Bucchioni, Massimo Caruso, Pascal Chanez, Barbro Dahlén, Sven-Erik Dahlen, Kerry Dyson, Urs Frey, Thomas Geiser, Maria Gerhardsson de Verdier, David Gibeon, Yi-ke Guo, Simone Hashimoto, Gunilla Hedlin, Elizabeth Jeyasingham, Pieter-Paul W. Hekking, Tim Higenbottam, Ildikó Horváth, Alan J. Knox, Norbert Krug, Veit J. Erpenbeck, Lars X. Larsson, Nikos Lazarinis, John G. Matthews, Roelinde Middelveld, Paolo Montuschi, Jacek Musial, David Myles, Laurie Pahus, Thomas Sandström, Wolfgang Seibold, Florian Singer, Karin Strandberg, Jorgen Vestbo, Nadja Vissing, Christophe von Garnier, Ian M. Adcock, Scott Wagers, Anthony Rowe, Peter Howarth, Ariane H. Wagener, Ratko Djukanovic, Peter J. Sterk and Kian Fan ChungArticle | Published in 2015 in European Respiratory JournalDominick E. Shaw1Respiratory Research Unit, University of Nottingham, Nottingham, UK44Joint first authorsAna R. Sousa2Respiratory Therapeutic Unit, GSK, Stockley Park, UK44Joint first authorsStephen J. Fowler3Respiratory and Allergy Research Group, University of Manchester, Manchester, UKLouise J. Fleming4National Heart and Lung Institute, Imperial College, London, UKGraham Roberts5NIHR Southampton Respiratory Biomedical Research Unit, Clinical and Experimental Sciences and Human Development and Health, Southampton, UK6Faculty of Medicine, University of Southampton, Southampton, UK7The David Hide Asthma and Allergy Research Centre, St Mary's Hospital, Isle of Wight, UKJulie Corfield8AstraZeneca R&D, Mölndal, Sweden9Areteva R&D, Nottingham, UKIoannis Pandis10Data Science Institute, South Kensington Campus, Imperial College London, London, UKAruna T. Bansal11Acclarogen Ltd, St John's Innovation Centre, Cambridge, UKElisabeth H. Bel12Dept of Respiratory Medicine, Academic Medical Centre, University of Amsterdam, Amsterdam, The NetherlandsCharles Auffray13European Institute for Systems Biology and Medicine, CNRS-ENS-UCBL, Université de Lyon, Lyon, FranceChris H. Compton2Respiratory Therapeutic Unit, GSK, Stockley Park, UKHans Bisgaard14Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, DenmarkEnrica Bucchioni15Chiesi Pharmacueticals SPA, Parma, ItalyMassimo Caruso16Dept of Clinical and Experimental Medicine Hospital University, University of Catania, Catania, ItalyPascal Chanez17Département des Maladies Respiratoires, Laboratoire d'immunologie, Aix Marseille Université Marseille, Marseille, FranceBarbro Dahlén18Lung/Allergy Clinic, Karolinska University Hospital Huddinge, Stockholm, SwedenSven-Erik Dahlen19The Centre for Allergy Research, The Institute of Environmental Medicine, Karolinska Institutet, Stockholm, SwedenKerry Dyson20CROMSOURCE, Stirling, UKUrs Frey21University Children's Hospital Basel, Basel, SwitzerlandThomas Geiser22University Hospital Bern, Bern, SwitzerlandMaria Gerhardsson de Verdier8AstraZeneca R&D, Mölndal, SwedenDavid Gibeon4National Heart and Lung Institute, Imperial College, London, UKYi-ke Guo10Data Science Institute, South Kensington Campus, Imperial College London, London, UKSimone Hashimoto12Dept of Respiratory Medicine, Academic Medical Centre, University of Amsterdam, Amsterdam, The NetherlandsGunilla Hedlin23Dept of Women's and Children's Health and Center for Allergy Research, Karolinska Institutet, Stockholm, SwedenElizabeth Jeyasingham24UK Clinical Operations, GSK, Stockley Park, UKPieter-Paul W. Hekking12Dept of Respiratory Medicine, Academic Medical Centre, University of Amsterdam, Amsterdam, The NetherlandsTim Higenbottam25Allergy Therapeutics, West Sussex, UKIldikó Horváth26Dept of Pulmonology, Semmelweis University, Budapest, HungaryAlan J. Knox1Respiratory Research Unit, University of Nottingham, Nottingham, UKNorbert Krug27Fraunhofer Institute for Toxicology and Experimental Medicine Hannover, Hannover, GermanyVeit J. Erpenbeck28Translational Medicine - Respiratory Profiling, Novartis Institutes for BioMedical Research, Basel, SwitzerlandLars X. Larsson8AstraZeneca R&D, Mölndal, SwedenNikos Lazarinis18Lung/Allergy Clinic, Karolinska University Hospital Huddinge, Stockholm, SwedenJohn G. Matthews29Respiratory and Allergic Diseases, Product Development Immunology, Genentech, San Francisco, CA, USARoelinde Middelveld20CROMSOURCE, Stirling, UKPaolo Montuschi30Faculty of Medicine, Catholic University of the Sacred Heart, Rome, ItalyJacek Musial31Dept of Medicine, Jagiellonian University Medical College, Krakow, PolandDavid Myles32Respiratory Therapy Area Unit, GlaxoSmithKline, Stevenage, UKLaurie Pahus33Assistance publique des Hôpitaux de Marseille, Hôpital NORD, Clinique des bronches, allergies et sommeil, Marseille, FranceThomas Sandström34Dept of Medicine, Dept of Public Health and Clinical Medicine Respiratory Medicine Unit, Umeå University, Umeå, SwedenWolfgang Seibold35Boehringer Ingelheim Pharma GmbH & Co., Ingelheim, GermanyFlorian Singer36University Children's Hospital Zurich, Zurich, SwitzerlandKarin Strandberg18Lung/Allergy Clinic, Karolinska University Hospital Huddinge, Stockholm, SwedenJorgen Vestbo37Respiratory Research Group, Manchester Academic Health Science Centre, University Hospital South Manchester NHS Foundation Trust, Manchester, UKNadja Vissing38The Danish Pediatric Asthma Center, University of Copenhagen, Copenhagen, DenmarkChristophe von Garnier22University Hospital Bern, Bern, Switzerland39Tiefenau Hospital, Bern, SwitzerlandIan M. Adcock4National Heart and Lung Institute, Imperial College, London, UK40Biomedical Research Unit, Royal Brompton & Harefield NHS Trust, London, UKScott Wagers41BioSci Consulting, Maasmechelen, BelgiumAnthony Rowe42Janssen Research and Development Ltd, High Wycombe, UKPeter Howarth43NIHR Southampton Respiratory Biomedical Research Unit, Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, UKAriane H. Wagener12Dept of Respiratory Medicine, Academic Medical Centre, University of Amsterdam, Amsterdam, The NetherlandsRatko Djukanovic43NIHR Southampton Respiratory Biomedical Research Unit, Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, UKPeter J. Sterk12Dept of Respiratory Medicine, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands45Joint last authorsKian Fan Chung4National Heart and Lung Institute, Imperial College, London, UK40Biomedical Research Unit, Royal Brompton & Harefield NHS Trust, London, UK45Joint last authors
- Clinical and inflammatory characteristics of the European U-BIOPRED adult severe asthma cohortBy Dominick E. Shaw, Ana R. Sousa, Stephen J. Fowler, Louise J. Fleming, Graham Roberts, Julie Corfield, Ioannis Pandis, Aruna T. Bansal, Elisabeth H. Bel, Charles Auffray, Chris H. Compton, Hans Bisgaard, Enrica Bucchioni, Massimo Caruso, Pascal Chanez, Barbro Dahlén, Sven-Erik Dahlen, Kerry Dyson, Urs Frey, Thomas Geiser, Maria Gerhardsson de Verdier, David Gibeon, Yi-ke Guo, Simone Hashimoto, Gunilla Hedlin, Elizabeth Jeyasingham, Pieter-Paul W. Hekking, Tim Higenbottam, Ildikó Horváth, Alan J. Knox, Norbert Krug, Veit J. Erpenbeck, Lars X. Larsson, Nikos Lazarinis, John G. Matthews, Roelinde Middelveld, Paolo Montuschi, Jacek Musial, David Myles, Laurie Pahus, Thomas Sandström, Wolfgang Seibold, Florian Singer, Karin Strandberg, Jorgen Vestbo, Nadja Vissing, Christophe von Garnier, Ian M. Adcock, Scott Wagers, Anthony Rowe, Peter Howarth, Ariane H. Wagener, Ratko Djukanovic, Peter J. Sterk and Kian Fan ChungDominick E. Shaw1Respiratory Research Unit, University of Nottingham, Nottingham, UK44Joint first authorsAna R. Sousa2Respiratory Therapeutic Unit, GSK, Stockley Park, UK44Joint first authorsStephen J. Fowler3Respiratory and Allergy Research Group, University of Manchester, Manchester, UKLouise J. Fleming4National Heart and Lung Institute, Imperial College, London, UKGraham Roberts5NIHR Southampton Respiratory Biomedical Research Unit, Clinical and Experimental Sciences and Human Development and Health, Southampton, UK6Faculty of Medicine, University of Southampton, Southampton, UK7The David Hide Asthma and Allergy Research Centre, St Mary's Hospital, Isle of Wight, UKJulie Corfield8AstraZeneca R&D, Mölndal, Sweden9Areteva R&D, Nottingham, UKIoannis Pandis10Data Science Institute, South Kensington Campus, Imperial College London, London, UKAruna T. Bansal11Acclarogen Ltd, St John's Innovation Centre, Cambridge, UKElisabeth H. Bel12Dept of Respiratory Medicine, Academic Medical Centre, University of Amsterdam, Amsterdam, The NetherlandsCharles Auffray13European Institute for Systems Biology and Medicine, CNRS-ENS-UCBL, Université de Lyon, Lyon, FranceChris H. Compton2Respiratory Therapeutic Unit, GSK, Stockley Park, UKHans Bisgaard14Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, DenmarkEnrica Bucchioni15Chiesi Pharmacueticals SPA, Parma, ItalyMassimo Caruso16Dept of Clinical and Experimental Medicine Hospital University, University of Catania, Catania, ItalyPascal Chanez17Département des Maladies Respiratoires, Laboratoire d'immunologie, Aix Marseille Université Marseille, Marseille, FranceBarbro Dahlén18Lung/Allergy Clinic, Karolinska University Hospital Huddinge, Stockholm, SwedenSven-Erik Dahlen19The Centre for Allergy Research, The Institute of Environmental Medicine, Karolinska Institutet, Stockholm, SwedenKerry Dyson20CROMSOURCE, Stirling, UKUrs Frey21University Children's Hospital Basel, Basel, SwitzerlandThomas Geiser22University Hospital Bern, Bern, SwitzerlandMaria Gerhardsson de Verdier8AstraZeneca R&D, Mölndal, SwedenDavid Gibeon4National Heart and Lung Institute, Imperial College, London, UKYi-ke Guo10Data Science Institute, South Kensington Campus, Imperial College London, London, UKSimone Hashimoto12Dept of Respiratory Medicine, Academic Medical Centre, University of Amsterdam, Amsterdam, The NetherlandsGunilla Hedlin23Dept of Women's and Children's Health and Center for Allergy Research, Karolinska Institutet, Stockholm, SwedenElizabeth Jeyasingham24UK Clinical Operations, GSK, Stockley Park, UKPieter-Paul W. Hekking12Dept of Respiratory Medicine, Academic Medical Centre, University of Amsterdam, Amsterdam, The NetherlandsTim Higenbottam25Allergy Therapeutics, West Sussex, UKIldikó Horváth26Dept of Pulmonology, Semmelweis University, Budapest, HungaryAlan J. Knox1Respiratory Research Unit, University of Nottingham, Nottingham, UKNorbert Krug27Fraunhofer Institute for Toxicology and Experimental Medicine Hannover, Hannover, GermanyVeit J. Erpenbeck28Translational Medicine - Respiratory Profiling, Novartis Institutes for BioMedical Research, Basel, SwitzerlandLars X. Larsson8AstraZeneca R&D, Mölndal, SwedenNikos Lazarinis18Lung/Allergy Clinic, Karolinska University Hospital Huddinge, Stockholm, SwedenJohn G. Matthews29Respiratory and Allergic Diseases, Product Development Immunology, Genentech, San Francisco, CA, USARoelinde Middelveld20CROMSOURCE, Stirling, UKPaolo Montuschi30Faculty of Medicine, Catholic University of the Sacred Heart, Rome, ItalyJacek Musial31Dept of Medicine, Jagiellonian University Medical College, Krakow, PolandDavid Myles32Respiratory Therapy Area Unit, GlaxoSmithKline, Stevenage, UKLaurie Pahus33Assistance publique des Hôpitaux de Marseille, Hôpital NORD, Clinique des bronches, allergies et sommeil, Marseille, FranceThomas Sandström34Dept of Medicine, Dept of Public Health and Clinical Medicine Respiratory Medicine Unit, Umeå University, Umeå, SwedenWolfgang Seibold35Boehringer Ingelheim Pharma GmbH & Co., Ingelheim, GermanyFlorian Singer36University Children's Hospital Zurich, Zurich, SwitzerlandKarin Strandberg18Lung/Allergy Clinic, Karolinska University Hospital Huddinge, Stockholm, SwedenJorgen Vestbo37Respiratory Research Group, Manchester Academic Health Science Centre, University Hospital South Manchester NHS Foundation Trust, Manchester, UKNadja Vissing38The Danish Pediatric Asthma Center, University of Copenhagen, Copenhagen, DenmarkChristophe von Garnier22University Hospital Bern, Bern, Switzerland39Tiefenau Hospital, Bern, SwitzerlandIan M. Adcock4National Heart and Lung Institute, Imperial College, London, UK40Biomedical Research Unit, Royal Brompton & Harefield NHS Trust, London, UKScott Wagers41BioSci Consulting, Maasmechelen, BelgiumAnthony Rowe42Janssen Research and Development Ltd, High Wycombe, UKPeter Howarth43NIHR Southampton Respiratory Biomedical Research Unit, Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, UKAriane H. Wagener12Dept of Respiratory Medicine, Academic Medical Centre, University of Amsterdam, Amsterdam, The NetherlandsRatko Djukanovic43NIHR Southampton Respiratory Biomedical Research Unit, Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, UKPeter J. Sterk12Dept of Respiratory Medicine, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands45Joint last authorsKian Fan Chung4National Heart and Lung Institute, Imperial College, London, UK40Biomedical Research Unit, Royal Brompton & Harefield NHS Trust, London, UK45Joint last authors
- QAW039 (fevipiprant) improves lung function and control of asthma symptoms in patients with more severe air flow limitation: A proof-of-concept studyBy Veit J. Erpenbeck, Todor A. Popov, S. David Miller, Steven F. Weinstein, Sheldon Spector, Baldur Magnusson, Wande Osuntokun, Paul Goldsmith, Markus Weiss and Jutta BeierVeit J. Erpenbeck1Novartis Pharma AG, Basel, SwitzerlandTodor A. Popov2Clinic of Allergy & Asthma, Medical University Sofia, Bulgaria, BulgariaS. David Miller3NEMRA, North Dartmouth, MA, United StatesSteven F. Weinstein4Allergy & Immunology, Allergy and Asthma Specialists Medical Group and Research Center, CA, United StatesSheldon Spector5Allergy & Asthma, California Allergy and Asthma Medical Group Inc, CA, United StatesBaldur Magnusson1Novartis Pharma AG, Basel, SwitzerlandWande Osuntokun6Novartis Pharmaceuticals, Horsham, United KingdomPaul Goldsmith6Novartis Pharmaceuticals, Horsham, United KingdomMarkus Weiss1Novartis Pharma AG, Basel, SwitzerlandJutta Beier7INSAF, Respiratory Research Institute GmbH, Wiesbaden, Germany
Buying books on this site
Purchases made on this website are of electronic books only.
About the ERS books
The ERS Monograph is the quarterly book series from the European Respiratory Society. Each Monograph covers a specific area of respiratory medicine, providing in-depth reviews that give clinicians at all levels a concise, comprehensive guide to symptoms, diagnosis and treatment.
The ERS Handbooks are compact guides to broad areas of the respiratory field. Launched in 2010, the series now covers adult, paediatric and sleep respiratory medicine, includes a companion volume of self-assessment questions and features the ERS Practical Handbooks.